New anti-diabetic compound class 'has fewer side effects'
Posted on 05 September 2011
A new class of anti-diabetic compound has been created, possible aiding those paying for care with the condition.
In a study carried out at the Scripps Research Institute, researchers established the new class of anti-diabetic compound which targets a unique molecular switch.
This discovery could lead the way for development of anti-diabetic medications with fewer side effects compared to currently used drugs such as Avandia, according to the research published in journal Nature.
Researcher Patrick R Griffin said: "In this study, we demonstrate that we have discovered novel compounds that work effectively through a unique mechanism of action on a well-validated clinical target for diabetes.
"This unique mechanism of action appears to significantly limit side effects associated with marketed drugs."
Meanwhile, a University of Missouri study has found that inactive individuals could be at a higher risk of type 2 diabetes, potentially increasing their need to look for ways to pay for care.
Posted by Natalie Edwards